I wrote earlier this week about Johnson & Johnson’s recall problems. In another blow to J&J’s image, US prosecutors are seeking $1 billion from Johnson & Johnson for off label (unapproved) marketing of its anti-psychotic drug, Risperdal. According to reports, prosecutors are pushing J&J to reach a settlement soon.
Atypical anti-psychotic drugs, like Risperdal, were designed to treat ailments like schizophrenia or bipolar disorder, but have been marketed and used extensively for "off label" or unapproved purposes. These drugs have serious side effects including tardive sykinesia, hyperglycemia, diabetes, pancreatitis, and heart attack.
Check with your physician if you have been prescribed Risperdal or other atypical anti-psychotic drugs.
More Information:
- Prosecutors Seek $1 Billion From J&J in Marketing Probe [Jonathan D. Rockoff and Joann S. Lublin]
- U.S. seeking $ billion from J&J in Risperdal probe: report [Ransdell Pierson at Reuters]
(c) Copyright Brett A. Emison
Brett Emison is currently a partner at Langdon & Emison, a firm dedicated to helping injured victims across the country from their primary office near Kansas City. Mainly focusing on catastrophic injury and death cases as well as complex mass tort and dangerous drug cases, Mr. Emison often deals with automotive defects, automobile crashes, railroad crossing accidents (train accidents), trucking accidents, dangerous and defective drugs, defective medical devices.
Comments for this article are closed.